Summit Therapeutics Inc.
SMMT
Rank in Stocks
#1702
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Share Price
$15.38
Market Cap
$12.27B
Change (1 day)
-1.25%
Change (1 year)
-23.28%
Country
US
Trade Summit Therapeutics Inc. (SMMT)
Category
Healthcare
Earnings for Summit Therapeutics Inc. (SMMT)
Earnings in Jun 2026 TTM: $-856.04M
According to Summit Therapeutics Inc. latest financial reports the company's current earnings are $-856.04M. In 2023 the company made an earning of $-615.87M, a decrease compared to its 2022 earnings that were of $-78.78M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Summit Therapeutics Inc. from 2004 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-856.04M | 286.80% |
| 2024 | $-221.32M | -64.06% |
| 2023 | $-615.87M | 681.74% |
| 2022 | $-78.78M | -11.08% |
| 2021 | $-88.60M | 67.46% |
| 2020 | $-52.91M | 40.45% |
| 2019 | $-37.67M | -21.65% |
| 2018 | $-48.08M | 18.85% |
| 2017 | $-40.45M | 22.47% |
| 2016 | $-33.03M | 73.25% |
| 2015 | $-19.07M | 4.94% |
| 2014 | $-18.17M | 58.92% |
| 2013 | $-11.43M | 54.03% |
| 2012 | $-7.42M | -50.39% |
| 2011 | $-14.96M | 0.25% |
| 2010 | $-14.92M | -44.98% |
| 2009 | $-27.12M | -37.83% |
| 2008 | $-43.63M | 223.51% |
| 2007 | $-13.49M | 249.34% |
| 2006 | $-3.86M | 1,451.88% |
| 2005 | $-248.74K | 226.26% |
| 2004 | $-76.24K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -716.20% |
US
|
|
| $-3.09B | 260.61% |
US
|
|
| $-4.02B | 369.16% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -327.87% |
NL
|
